Parkinsonian patients with hypersalivation
Conditions
Interventions
Cross over design: In week 2 glycopyrroniumbromide (3 times 1mg=5ml daily) or placebo (3 times 5ml daily ). In week 4 cross-over glycopyrroniumbromide (3 times 1mg=5ml daily) or placebo (3 times 5ml d
Sponsors
M.E.L. Arbouw,
Hospital Medisch Spectrum TwenteDepartment of clinical pharmacy
P.O. Box 50.000
7500 KA Enschede
The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Parkinson's disease; 2. Age >=18 years; 3. Hypersalivation score >=5 (on a scale from 1-9); 4. Patient or family is able to score the extent of hypersalivation.
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to glycopyrronium bromide, sorbic acid or saccharin sodium; 2. Myasthenia gravis; 3. Symptomatic tachycardia; 4. Coronary insufficiency; 5. Heart rythm disorders; 6. Glaucoma; 7. Pylorus stenosis; 8. Paralytic ileus; 9. Prostate hypertrophy; 10 Patients using potassiumchloride tablets, oral digoxin or oral corticosteroids; 11. Kidney function disorders; 12. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with a decrease of 3 points on the hypersalivation score (on a scale from 1-9). | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference in mean improvement on the hypersalivation score between the two groups. Furthermore, the difference in reported adverse events will be analysed. | — |
Contacts
Public ContactP.J.E. Poels
Hospital Medisch Spectrum Twente, Department of neurology P.O. Box 50.000
Outcome results
None listed